Tiziana Life Sciences prices downsized $4 million US offering at $9.90

Tiziana Life Sciences, which is developing antibody therapies to combat NASH, Crohn's disease, MS, and cancer, raised $4.4 million by offering 442,910 shares at $9.90. The offer price is roughly equal to the as-converted price of Tiziana's common shares listed on London's AIM (AIM: TILS). Because the company's Nasdaq IPO raised less than $5.0 million, Renaissance Capital is excluding the deal from its 2018 IPO stats.

In addition to the $4.4 million raised in the US IPO, Tiziana disclosed that it had raised $1.5 million in an equity offering in late October, raised $1.4 million by issuing shares from an exercised warrant, and issued new shares to extinguish $1.8 million in debt.

Tiziana Life Sciences plans to list on the Nasdaq under the symbol TLSA. Laidlaw & Company (UK) acted as a lead manager on the deal.

The article Tiziana Life Sciences prices downsized $4 million US offering at $9.90 originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.